Barinthus Biotherapeutics has announced a strategic shift towards immunology and inflammation (I&I) indications, prioritizing the development of VTP-1000 for celiac disease and postponing further development of VTP-300 for chronic hepatitis B until a partner is found. The company also revealed a financial restructuring plan, including a significant workforce reduction and the closure of its U.K. site, to extend its cash runway to the start of 2027.
Barinthus Bio has commenced a Phase 1 clinical trial for VTP-1000, an investigational immunotherapy for celiac disease, a condition affecting approximately one in 100 people globally.